Hologic (HOLX) Stock Rating Reaffirmed by Needham & Company LLC

Needham & Company LLC reiterated their buy rating on shares of Hologic (NASDAQ:HOLX) in a research note published on Tuesday morning, Marketbeat Ratings reports. The brokerage currently has a $50.00 price target on the medical equipment provider’s stock, up from their prior price target of $48.00.

HOLX has been the topic of a number of other reports. Cowen raised shares of Hologic to a buy rating and set a $52.00 price objective on the stock in a research note on Wednesday, December 20th. Zacks Investment Research raised shares of Hologic from a sell rating to a hold rating in a research note on Tuesday, October 31st. Goldman Sachs Group raised shares of Hologic from a buy rating to a conviction-buy rating and upped their price objective for the company from $45.00 to $50.00 in a research note on Friday, December 8th. Stifel Nicolaus reaffirmed a buy rating and issued a $45.00 price objective (down from $48.00) on shares of Hologic in a research note on Monday, October 9th. Finally, Jefferies Group reaffirmed a buy rating and issued a $44.00 price objective (down from $49.00) on shares of Hologic in a research note on Tuesday, October 10th. One equities research analyst has rated the stock with a sell rating, three have given a hold rating, eleven have issued a buy rating and one has given a strong buy rating to the stock. Hologic currently has a consensus rating of Buy and an average target price of $48.79.

Hologic (HOLX) traded up $0.16 during trading hours on Tuesday, hitting $43.71. 3,060,034 shares of the stock were exchanged, compared to its average volume of 1,908,935. The company has a debt-to-equity ratio of 0.79, a quick ratio of 0.61 and a current ratio of 0.79. Hologic has a 12 month low of $35.76 and a 12 month high of $46.80. The company has a market cap of $12,006.02, a price-to-earnings ratio of 16.56, a P/E/G ratio of 2.08 and a beta of 0.95.

Hologic (NASDAQ:HOLX) last posted its quarterly earnings data on Wednesday, November 8th. The medical equipment provider reported $0.50 EPS for the quarter, beating the Zacks’ consensus estimate of $0.49 by $0.01. Hologic had a net margin of 24.70% and a return on equity of 21.69%. The company had revenue of $802.90 million for the quarter, compared to analyst estimates of $792.54 million. During the same period in the prior year, the firm posted $0.52 EPS. The company’s quarterly revenue was up 10.5% on a year-over-year basis. equities analysts expect that Hologic will post 2.15 EPS for the current year.

In related news, Director Elaine Ullian sold 9,282 shares of the business’s stock in a transaction on Monday, November 13th. The shares were sold at an average price of $40.50, for a total transaction of $375,921.00. The transaction was disclosed in a filing with the SEC, which is available at this hyperlink. Also, VP Karleen Marie Oberton sold 1,023 shares of the business’s stock in a transaction on Monday, November 20th. The shares were sold at an average price of $39.84, for a total transaction of $40,756.32. The disclosure for this sale can be found here. Insiders have sold a total of 12,099 shares of company stock worth $487,223 in the last quarter. 0.79% of the stock is owned by corporate insiders.

Institutional investors have recently added to or reduced their stakes in the stock. Koch Industries Inc. raised its holdings in Hologic by 15,554.1% during the second quarter. Koch Industries Inc. now owns 1,149,481 shares of the medical equipment provider’s stock worth $1,125,000 after buying an additional 1,142,138 shares during the last quarter. Picton Mahoney Asset Management raised its holdings in Hologic by 8.1% during the second quarter. Picton Mahoney Asset Management now owns 57,150 shares of the medical equipment provider’s stock worth $2,593,000 after buying an additional 4,300 shares during the last quarter. Chevy Chase Trust Holdings Inc. raised its holdings in Hologic by 1.4% during the third quarter. Chevy Chase Trust Holdings Inc. now owns 244,620 shares of the medical equipment provider’s stock worth $8,975,000 after buying an additional 3,391 shares during the last quarter. Royce & Associates LP acquired a new position in Hologic during the second quarter worth $908,000. Finally, Cipher Capital LP raised its holdings in Hologic by 57.9% during the third quarter. Cipher Capital LP now owns 117,673 shares of the medical equipment provider’s stock worth $4,317,000 after buying an additional 43,146 shares during the last quarter. Institutional investors own 97.67% of the company’s stock.

TRADEMARK VIOLATION WARNING: “Hologic (HOLX) Stock Rating Reaffirmed by Needham & Company LLC” was reported by Dispatch Tribunal and is the property of of Dispatch Tribunal. If you are accessing this story on another domain, it was illegally stolen and republished in violation of U.S. and international trademark and copyright laws. The legal version of this story can be read at https://www.dispatchtribunal.com/2018/01/13/hologic-holx-stock-rating-reaffirmed-by-needham-company-llc.html.

Hologic Company Profile

Hologic, Inc is a developer, manufacturer and supplier of diagnostics products, medical imaging systems and surgical products with an emphasis on women’s health. The Company operates through four segments: Diagnostics, Breast Health, GYN Surgical and Skeletal Health. The diagnostics products include Aptima family of assays, ThinPrep system, the Rapid Fetal Fibronectin Test and Procleix blood screening assays.

Analyst Recommendations for Hologic (NASDAQ:HOLX)

Receive News & Ratings for Hologic Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Hologic and related companies with MarketBeat.com's FREE daily email newsletter.

Leave a Reply